A new combination Haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants
Boutriau D., Pollard AJ.
We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. SBA MenC titers ≥1:8 and anti-PRP concentrations ≥0.15 μg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT. © 2007 Lippincott Williams & Wilkins, Inc.